In a 2009–2011 Phase II clinical trial including 464 MS patients,<unk>  treatment resulted in fewer new active brain lesions than placebo, measured during the course of 24 weeks. In a 2010–2012 Phase II clinical trial including 326 patients with psoriasis, 46 or 48% of patients (depending on dosage) had a reduction of at least 75% Psoriasis Area and Severity Index (PASI) score compared to placebo in 16 weeks. The approval is already applied for in 2020. In a 2015–2019 Phase III randomised, double-blind clinical trial of 1133 adult patients with relapsing MS, those under<unk>  treatment showed a 30% reduction in annual relapse rate and a significantly reduced number of new inflammatory lesions on brain MRI by 56% compared to those taking teriflunomide.
Ponesimod
Ozanimod
Siponimod
Fingolimod
Caplacizumab
Sarilumab
Benralizumab
Atezolizumab